Overview

GATC Health uses artificial intelligence to speed up drug discovery and disease prediction. Its MAT platform analyzes genomics, proteomics, and metabolomics with AI and neural networks to identify drug targets, design candidates, and predict safety and efficacy before lab testing, processing 400 trillion data points in under eight minutes with UC Irvine validation. It both develops its own drug candidates and partners with pharma and biotech firms to accelerate development, de-risk pipelines, and reassess failed assets, including a partnership with MCI to forecast trial endpoints for underwriting clinical trials. Its goal is to shorten the time and cost to bring drugs to market and to change how clinical trial financing works by providing predictive insights that reduce risk.